Manic fringe promotes a claudin-low breast cancer phenotype through notch-mediated PIK3CG induction.

Claudin-low breast cancer (CLBC) is a poor prognosis disease biologically characterized by stemness and mesenchymal features. These tumors disproportionately affect younger patients and women with African ancestry, causing significant morbidity and mortality, and no effective targeted therapy exists at present. CLBC is thought to originate from mammary stem cells, but little is known on how or why these tumors express a stable epithelial-to-mesenchymal transition phenotype, or what are the driving forces of this disease. Here, we report that Manic Fringe (Mfng), which encodes an O-fucosylpeptide 3-β-N-acetylglucosaminyltransferase known to modify EGF repeats in the Notch extracellular domain, is highly expressed in CLBC and functions as an oncogene in this context. We show that Mfng modulates Notch activation in human and mouse CLBC cell lines, as well as in mouse mammary gland. Mfng silencing in CLBC cell lines reduced cell migration, tumorsphere formation, and in vivo tumorigenicity associated with a decrease in the stem-like cell population. Mfng deletion in the Lfng(flox/flox);MMTV-Cre mouse model, in which one-third of mammary tumors resemble human CLBC, caused a tumor subtype shift away from CLBC. We identified the phosphoinositide kinase Pik3cg as a direct transcriptional target of Mfng-facilitated RBPJκ-dependent Notch signaling. Indeed, pharmacologic inhibition of PI3Kγ in CLBC cell lines blocked migration and tumorsphere formation. Taken together, our results define Mfng as an oncogene acting through Notch-mediated induction of Pik3cg. Furthermore, they suggest that targeting PI3Kγ may prove beneficial for the treatment of CLBC subtype.

[1]  Connie J. Eaves,et al.  Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin , 2007 .

[2]  C. Perou,et al.  Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer. , 2012, Cancer cell.

[3]  S. McColl,et al.  Differential roles for the p101 and p84 regulatory subunits of PI3Kγ in tumor growth and metastasis , 2012, Oncogene.

[4]  R. Clarke,et al.  Breast cancer stem cells: something out of notching? , 2010, Cancer research.

[5]  P. Abel,et al.  Identification of upregulated phosphoinositide 3-kinase γ as a target to suppress breast cancer cell migration and invasion. , 2013, Biochemical pharmacology.

[6]  K. Irvine,et al.  Glycosylation regulates Notch signalling , 2003, Nature Reviews Molecular Cell Biology.

[7]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[8]  A. Minn,et al.  Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses , 2013, EMBO molecular medicine.

[9]  Marco Marra,et al.  Transcriptome analysis of the normal human mammary cell commitment and differentiation process. , 2008, Cell stem cell.

[10]  R. Clarke,et al.  Tumor and Stem Cell Biology Cancer Research Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch 4 Receptor , 2010 .

[11]  Kevin W Eliceiri,et al.  Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2 , 2011, Nature Medicine.

[12]  Charles M. Perou,et al.  Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes , 2011, Breast Cancer Research and Treatment.

[13]  Keli Xu,et al.  NOTch just a bladder control problem. , 2014, Cancer cell.

[14]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Karsan,et al.  Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. , 2007, The Journal of experimental medicine.

[16]  Jason I. Herschkowitz,et al.  Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts , 2013, Genome Biology.

[17]  R. Weinberg,et al.  Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. , 2012, Seminars in cancer biology.

[18]  Keli Xu,et al.  Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer , 2014, Cancer biology & therapy.

[19]  L. Magnani,et al.  Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells , 2014, Breast Cancer Research.

[20]  Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes , 2011 .

[21]  Jacques Colinge,et al.  A chemical genetic screen reveals a resistance mechanism to PI3K inhibitors in cancer , 2011, Nature chemical biology.

[22]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[23]  Sendurai A Mani,et al.  The Epithelial-to-Mesenchymal Transition and Cancer Stem Cells: A Coalition Against Cancer Therapies , 2009, Journal of Mammary Gland Biology and Neoplasia.

[24]  H. Kiaris,et al.  Notch3 marks clonogenic mammary luminal progenitor cells in vivo , 2013, The Journal of cell biology.

[25]  J. Visvader,et al.  Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. , 2008, Cell stem cell.